Bridges Investment Management Inc. Acquires 3,377 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Bridges Investment Management Inc. increased its holdings in Thermo Fisher Scientific Inc. by 2.4%, acquiring an additional 3,377 shares during the 2nd quarter, bringing their total to 143,614 shares valued at approximately $58.23 million.
• The company's latest earnings report revealed $10.86 billion in revenue for the quarter, surpassing analysts' expectations, and included an earnings per share of $5.36, beating the consensus estimate by $0.14.
• Major institutional investors have increased their stakes in Thermo Fisher Scientific, with institutional ownership reaching 89.23% of the company's stock, indicating strong confidence from large investors.

Bridges Investment Management Inc. raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 143,614 shares of the medical research company's stock after purchasing an additional 3,377 shares during the quarter. Bridges Investment Management Inc.'s holdings in Thermo Fisher Scientific were worth $58,230,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Mondrian Investment Partners LTD raised its position in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock valued at $106,738,000 after purchasing an additional 127,357 shares during the last quarter. Caledonia Investments PLC raised its position in Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company's stock valued at $45,299,000 after purchasing an additional 11,500 shares during the last quarter. Foresight Group Ltd Liability Partnership increased its stake in shares of Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock valued at $29,113,000 after buying an additional 56,747 shares during the period. Advisors Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock valued at $63,201,000 after buying an additional 7,967 shares during the period. Finally, New England Research & Management Inc. increased its stake in shares of Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company's stock valued at $1,033,000 after buying an additional 567 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 0.3%

NYSE:TMO opened at $527.34 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market cap of $199.13 billion, a price-to-earnings ratio of 30.50, a PEG ratio of 2.85 and a beta of 0.77. The stock has a 50-day moving average price of $492.55 and a two-hundred day moving average price of $448.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the previous year, the firm earned $5.37 earnings per share. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Barclays lifted their target price on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a research note on Thursday, October 2nd. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Finally, Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $589.10.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.